Eli Lilly and Veeva Lead 2026 Growth Outlook Amid AI-Driven Pharma Shift
Key Takeaways
- As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration.
- With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
Mentioned
Key Intelligence
Key Facts
- 1Tirzepatide became the world's best-selling drug in 2025 following massive adoption in obesity markets.
- 2Eli Lilly is scheduled to launch orforglipron, a highly anticipated oral GLP-1 drug, in 2026.
- 3SoundHound AI reported 59% revenue growth in Q4 2025, driven by expansion into service automation.
- 4Nebius projects its annual run rate (ARR) to reach $7B-$9B by the end of 2026, up from $1.25B.
- 5Eli Lilly's revenue growth rates are currently exceeding the mid-double-digit industry average for large-cap pharma.
Who's Affected
Analysis
The pharmaceutical sector is undergoing a fundamental transformation in early 2026, characterized by the convergence of metabolic medicine and generative artificial intelligence. As equity markets experience heightened volatility, institutional focus has shifted toward high-conviction growth stocks that demonstrate both defensive resilience and tech-sector-style revenue acceleration. Eli Lilly (LLY) stands at the epicenter of this shift, having transitioned from a traditional big-pharma profile to a high-growth powerhouse, largely on the back of its dominant position in the incretin mimetic market. This evolution is not merely a result of blockbuster sales but a reflection of a deeper strategic pivot toward data-driven therapeutic development.
The success of tirzepatide, which secured its status as the world’s best-selling pharmaceutical product in 2025, has provided Eli Lilly with a massive capital buffer to reinvest in its next generation of therapies. The anticipated 2026 launch of orforglipron, an oral GLP-1 receptor agonist, represents a critical pivot point for the company. By moving away from injectable-only administration, Lilly is poised to capture a broader patient demographic and mitigate the needle fatigue that often limits long-term adherence in obesity and type 2 diabetes treatments. This oral formulation is not merely a line extension but a strategic moat against competitors who remain tethered to complex cold-chain logistics for injectable biologics. The market for anti-obesity medicines is expanding at an unprecedented rate, and Lilly’s ability to iterate on its delivery mechanisms ensures it stays ahead of the curve.
Investors should also note the explosive growth of infrastructure providers like Nebius, which is projected to see its annual run rate jump from $1.25 billion to as much as $9 billion by the end of 2026.
Beyond metabolic health, the integration of AI-powered drug discovery is redefining Lilly’s operational efficiency. The company’s heavy investment in generative AI and machine learning models has begun to shorten the lead time between lead optimization and Phase 1 clinical trials. This technological edge is mirrored in the broader market by the rise of specialized AI firms like SoundHound AI and Nebius. SoundHound AI, despite being down approximately 60% from its all-time high, presents a compelling case for the integration of audio-AI in healthcare. Its technology, which combines audio recognition with generative AI, is increasingly being targeted at medical and insurance customer service roles—sectors where high administrative costs have long been a bottleneck. If SoundHound can successfully transition its drive-thru automation success into the complex world of medical billing and patient interaction, it could become a foundational layer of the healthcare administrative stack.
For companies like Veeva Systems, which provides the cloud infrastructure for life sciences, this surge in data-heavy drug development creates a sustained tailwind for their CRM and data vault services. Veeva’s role as the digital backbone of the industry is more critical than ever as pharmaceutical companies move away from legacy systems toward unified, cloud-based platforms that can handle the massive datasets generated by modern clinical trials. The synergy between Veeva’s data management and Lilly’s therapeutic innovation highlights a broader trend: the most successful pharma companies in 2026 are those that operate like technology firms.
What to Watch
Investors should also note the explosive growth of infrastructure providers like Nebius, which is projected to see its annual run rate jump from $1.25 billion to as much as $9 billion by the end of 2026. This suggests that the picks and shovels of the AI revolution are finding deep utility in the biotech sector, where high-performance computing is required for genomic sequencing and protein folding simulations. The volatility seen in early 2026, while daunting for retail investors, offers a strategic entry point for those targeting companies with robust pipelines and technological moats.
Looking ahead, the second half of 2026 will likely be defined by the regulatory reception of Lilly’s neuroscience and oncology pipelines. With tirzepatide providing the revenue floor, the market is now pricing in the optionality of Lilly’s Alzheimer’s and immunology candidates. For Veeva, the transition of the industry toward more personalized, data-driven medicine ensures that their platform remains indispensable. The synergy between these two leaders—one providing the therapeutic breakthroughs and the other the digital architecture—creates a compelling narrative for growth-oriented portfolios in the current fiscal year. As the industry matures, the distinction between biotech and tech continues to blur, favoring those with the foresight to invest in both.